LES LABORATOIRES SERVIER;SHANGAI INSTITUTE OF PHARMACEUTICAL INDUSTRY
发明人:
DAVID LAFARGUE,PHILIPPE LETELLIER,YUHUI SHEN,JEAN PEAN,YING MANUEL - LUO,HANBIN SHAN,MICHAEL LYNCH,CECILE POIRIER
申请号：
ARP130103199
公开号：
AR092485A1
申请日:
2013.09.09
申请国别(地区):
AR
年份:
2015
代理人:
摘要：
Stabilized Amorphous form of the compound of formula (1). Claim 2: stabilized Amorphous form of agomelatine according to claim 1, characterized in that agomelatine is dispersed within a Matrix. Claim 3: stabilized Amorphous form of agomelatine according to claim 2, wherein the matrix used is an organic Polymer.Claim 5: stabilized Amorphous form of agomelatine according to claim 4, wherein the matrix used is eudragit L100.Claim 16: procedure for obtaining a stabilized Amorphous form of agomelatine according to any one of claims 1 to 15, wherein the compound of formula (1) obtained by any procedure and in any form, Crystal Complex, co Cris Such Salts and addition to a pharmaceutically acceptable acid or a base.Mixed with the polymer selected within one or several Solvents to obtain a complete dissolution of the components and the Solvent completely Evaporated under Reduced Pressure.Claim 17: procedure for obtaining a stabilized Amorphous form of agomelatine according to any one of claims 1 to 15, wherein the combined and premix Compound of formula (1) obtained by any procedure and in any form Crystal INA, Complex salts, co Crystals or Addendum to a pharmaceutically acceptable acid or a base.With the chosen Polymer is introduced into an Extruder in which the passage of Thyme and temperature are adjusted according to the viscosity of the mixture, Extruding to obtain one that is cut to the desired dimension and eventually Crushed.Forma amorfa estabilizada del compuesto de fórmula (1). Reivindicación 2: Forma amorfa estabilizada de la agomelatina según la reivindicación 1 caracterizada porque la agomelatina se dispersa en el seno de una matriz. Reivindicación 3: Forma amorfa estabilizada de la agomelatina según la reivindicación 2, caracterizada porque la matriz utilizada es un polímero orgánico. Reivindicación 5: Forma amorfa estabilizada de la agomelatina según la reivindicación 4, caracterizada porque la matriz utilizada es Eudragit L100. Reivindicación 16: Procedimien
